Evidence map›Paper›PMID 36289899›Full record

ArticleBiomedicines2022

Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker.

Chiara Bazzichetto, Michele Milella, Ilaria Zampiva, Francesca Simionato, Carla Azzurra Amoreo, Simonetta Buglioni, Chiara Pacelli, Loredana Le Pera, Teresa Colombo, Emilio Bria and 4 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Prognostic significance of pre-intervention circulating cytokines in digestive system cancers: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Interleukin-8 in health and disease.Molecular biomedicine · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Chiara BazzichettoPreclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-1648-3700
Michele MilellaSection of Oncology, Department of Medicine, University of Verona-School of Medicine and Verona University Hospital Trust, 37134 Verona, Italy.
Ilaria ZampivaSection of Oncology, Department of Medicine, University of Verona-School of Medicine and Verona University Hospital Trust, 37134 Verona, Italy.ORCID 0000-0003-4858-3965
Francesca SimionatoDepartment of Oncology, San Bortolo General Hospital, 36100 Vicenza, Italy.
Carla Azzurra AmoreoPathology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Simonetta BuglioniPathology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-5066-1523
Chiara PacelliDepartment of Biochemical Sciences "A. Rossi Fanelli", Sapienza University of Rome, 00185 Rome, Italy.
Loredana Le PeraServizio Grandi Strumentazioni e Core Facilities, Istituto Superiore di Sanità (ISS), 00161 Rome, Italy.ORCID 0000-0002-0076-9878
Teresa ColomboInstitute of Molecular Biology and Pathology-National Research Council (IBPM-CNR), 00185 Rome, Italy.ORCID 0000-0003-2415-7507
Emilio BriaMedical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0000-0002-2333-704X
Massimo ZeuliMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Donatella Del BufaloPreclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Isabella SperdutiBiostatistics Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0001-5115-3099
Fabiana ConciatoriPreclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-8579-5222
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Verona · ITInstitute of Molecular Biology and Pathology · ITIstituto Superiore di Sanità · ITOspedale San Bortolo · ITSapienza University of Rome · ITUniversità Cattolica del Sacro Cuore · IT

Funding

Bando Interno Ricerca Corrente IRE 2021 n.a.Italian Association for Cancer Research AIRC IG 20583Italian Association for Cancer Research n.a.Ministero della Salute FIMPCUP_J38D19000690001Ministry of Education, Universities and Research B39J21037270006
6 · The paper itself

Abstract

Among soluble actors that have emerged as druggable factors, the chemokine interleukin-8 (IL-8) has emerged as a possible determinant of response to immunotherapy and targeted treatment in several cancer types; however, its prognostic/predictive role in colorectal cancer (CRC) remains to be established. We: (i) conducted a systematic review of published literature on IL-8 expression in CRC; (ii) searched public transcriptomics databases; (iii) investigated IL-8 expression, by tumor and infiltrating cells, in a series of CRC samples; and (iv) carried out a meta-analysis of published literature correlating IL-8 expression and CRC prognosis. IL-8 possesses an important role as a mediator of the bidirectional crosstalk between tumor/stromal cells. Transcriptomic analysis indicated that specific IL-8 transcripts were significantly overexpressed in CRC compared to normal colon mucosa. Moreover, in our series we observed a statistically significant correlation between PTEN-loss and IL-8 expression by infiltrating mononuclear and tumor cells. In total, 12 papers met our meta-analysis inclusion criteria, demonstrating that high IL-8 levels significantly correlated with shorter overall survival and progression-free survival. Sensitivity analysis demonstrated a highly significant correlation with outcome for circulating, but not for tissue-detected, IL-8. IL-8 is overexpressed in CRC tissues and differentially produced by tumor or stromal components depending on CRC genetic background. Moreover, circulating IL-8 represents a strong prognostic factor in CRC, suggesting its use in the refining of prognostic CRC assessment and potentially the tailoring of therapeutic strategies in individual CRC patients.

Indexed as

advanced CRCanti-angiogenic drugschemotherapyIL-8prognosistumor–stroma interactions

Identifiers

PMID36289899
PMCPMC9599846
OpenAlexW4306839875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.